The Supervisory Board of Sartorius AG has extended the appointment of Dr. René Faber as a member of the Executive Board for an additional five-year period, through December 31, 2031. The decision, announced on March 26, 2026, reflects the board's confidence in Faber's leadership of the company's Bioprocess Solutions Division, a key growth driver as the biopharmaceutical industry expands its manufacturing capacity for biologics, vaccines, and cell and gene therapies.
René Faber, 50, holds a Ph.D. in polymer chemistry from the Technical University of Munich and has been with Sartorius since 2002, starting as a scientist. He progressed through various management roles before joining the Executive Board in January 2019. His extended tenure ensures strategic continuity in the Bioprocess Solutions Division, which provides single-use solutions for biotech drug production. According to the company, the division's portfolio supports safer, faster, and more sustainable manufacturing processes, a priority as the industry seeks to meet rising global demand.
The extension comes as Sartorius reported 2025 sales of approximately €3.5 billion, with over 14,000 employees across 60 production and sales sites worldwide. The company's Lab Products & Services Division serves research and quality assurance labs, while the Bioprocess Solutions Division focuses on upstream and downstream bioprocessing. Sartorius regularly complements its organic growth with acquisitions of complementary technologies, a strategy that has strengthened its market position.
Faber's reappointment aligns with Sartorius's long-term financial calendar, which includes upcoming results announcements: first-quarter results on April 23, 2026; half-year results on July 23, 2026; and nine-month results on October 22, 2026. The company's consistent leadership is expected to support its goal of being a leading partner to the biopharmaceutical industry, particularly as global regulatory frameworks evolve and demand for advanced therapies increases.
For more details on Faber's background, see his CV. Additional information about Sartorius's financial events can be found in its financial calendar.
